Scrutiny Over Medicare Transaction Facilitator Program's Impact on Pharmacies

The Medicare Transaction Facilitator (MTF) program, designed to help pharmacies manage costs through federally negotiated prices and dispensing fees, is facing scrutiny due to data inconsistencies. The average Part D dispensing fees range between $0.00 and $7.15, with a typical fee of $0.65. These figures fall short compared to the average retail dispensing cost of $15.00 and $90.50 for specialty dispensing, highlighting a financial shortfall that both community and specialty pharmacies are forced to absorb.

This financial gap hits rural pharmacies the hardest, where lower operational volumes make it challenging to offset losses. Approximately 10% of independent rural pharmacies closed between 2013 and 2022, underscoring the threat posed by the current reimbursement framework to access in these areas. Studies by the University of Southern California and the National Community Pharmacists Association (NCPA) indicate that many U.S. neighborhoods experience pharmacy shortages, with rural counties particularly affected.

The MTF's allowance for pharmacy benefits managers (PBMs) to set fees through negotiations has led to inadequate reimbursements, forcing some pharmacies to reconsider stocking specific drugs. An NCPA survey shows that most independent pharmacists view these reimbursement terms as detrimental to their business sustainability.

The challenges for specialty pharmacies are intensified by complex logistics and patient management demands, often leading to significant cash-flow strains. Delays in manufacturer refunds result in notable weekly and annual losses per pharmacy, further exacerbating financial pressures.

Pharmacists and industry organizations are pushing for policy changes. The Consolidated Appropriations Act of 2026 requires the Centers for Medicare and Medicaid Services (CMS) to establish and enforce reasonable reimbursement terms. This initiative presents an opportunity for pharmacists to influence the establishment of reimbursement floors that accurately reflect dispensing costs.

With medical care prices rising substantially over the years, aligning reimbursement floors with pharmacy sector-specific inflation is crucial. Such measures aim to ensure the sustainability of community pharmacies and prevent future financial disparities. Reports from the Federal Trade Commission highlight that a few dominant PBMs control a significant share of the U.S. prescription market. This concentration, alongside inadequate reimbursements, emphasizes the need for reforms to secure equitable compensation and preserve the viability of community pharmacies nationwide.